Cite
HARVARD Citation
Krop, I. et al. (n.d.). Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet oncology. 17 (6), pp. 811-821. [Online].